Novo Nordisk to acquire obesity drug developer Inversago, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

Inversago is a privately owned company which develops therapies pitched at people with obesity, diabetes and metabolic disorders, the Novo Nordisk said in its second-quarter report. Inversago’s lead asset is INV-202, a cannabinoid receptor blocker, which has shown weight loss in a phase 1b trial and is now in phase 2 development., Inversago is a privately owned company which develops therapies pitched at people with obesity, diabetes and metabolic disorders, the Novo Nordisk said in its second-quarter report. Inversago’s lead asset is INV-202, a cannabinoid receptor blocker, which has shown weight loss in a phase 1b trial and is now in phase 2 development., , Read More